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Abstract 
Poor solubility of drug compounds is a great issue in drug industry today and decreasing particle size is one 
efficient and simple way to overcome this challenge. Drug nanocrystals are solid nanosized drug particles, 
which are covered by a stabilizer layer. In nanoscale many physical properties, like compound solubility, are 
different from the solubility of bulk material, and due to this drug nanocrystals can reach supersaturation 
as compared to thermodynamic solubility. The most important effect of the smaller particle size is that 
dissolution rate is highly enhanced mainly due to the increased surface area. In this review the most 
important properties of nanocrystalline drug compounds are presented, with multiple examples of the 
development and characterization of nanocrystalline drug formulations.    
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Introduction 
Today more and more new APIs are poorly soluble, and poor solubility is an important issue in drug 
discovery and development. Efficient screening methods find increasing numbers of poorly soluble drug 
candidates for company pipelines and it has been approximated lately that 90% of the new chemical 
entities are poorly soluble. In Biopharmaceutics Classification System (BCS), these compounds belong to 
BCS class II (70%) or class IV (20%) (Loftsson and Brewster, 2010; Müller and Keck, 2012).   
There are different ways to improve the solubility of compounds. In molecular level prodrugs (Huttunen et 
al., 2011), salt formation (Serajuddin, 2007), co-solvent systems (Seedher and Kanojia, 2009) or 
cyclodextrins (Bilensoy and Hincal, 2009) can be beneficial. In particulate level utilization of metastable 
polymorphs (Blagden et al., 2007), co-crystals (Thakuria et al., 2013), amorphous systems (Babu and 
Nangia, 2011) or particle size reduction (Tuomela et al., 2015) have been studied intensively. A third 
approach for solubility/dissolution enhancement are colloidal systems, like SEDDS/SMEDDS/SNEDDS (Thi et 
al., 2009), (micro/nano)emulsions (Shakeel and Faisal, 2010) or different kinds of other lipid based systems 
like lipid solutions (Porter et al., 2007). Based on the physicochemical properties of the drug molecule, the 
most suitable way to improve the solubility should be selected (Shakeel and Faisal, 2010; Chen et al., 2011; 
Brough and Williams III, 2013).   
Drug nanocrystals are solid nanosized drug particles, which are covered by a stabilizer layer, and they are 
mostly utilized for increasing the solubility properties of poorly soluble drugs (Lu et al., 2016). In BCS 
system, class II drugs are poorly soluble but well permeable, and those are the most prominent candidates 
for drug nanocrystals (Liu et al., 2011; Borchard, 2015), but in some cases also BCS class IV drugs, poorly 
soluble and poorly permeable, may benefit from decreased particle size (Kesisoglou et al., 2007; Gao et al. 
2012). For example, a higher concentration gradient between the intestine and lumen (reached with higher 
and faster drug solubility) may lead also to improved drug permeation.      
With a closer focus on drug developability criteria, BCS class II drugs can still be classified into two 
subclasses according to the developability classification system (DCS): dissolution rate limited class IIa, the 
so called brick-dust molecules, and solubility limited class IIb, also known as the grease ball molecules 
(Butler and Dressman, 2010). Brick-dust molecules are poorly soluble not only in aqueous environment but 
also in lipids and organic solvents, while grease ball molecules are normally soluble in at least some lipids 
(Bergström et al., 2016). Brick dust molecules are, therefore, the best candidates for nanosizing (Borchard, 
2015). For grease ball molecules the first choice is lipid formulations, but they have also been formulated 
successfully to nanocrystals (Rydberg et al., 2016).     
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Production of nanocrystals is just one way to modify the intrinsic properties of the raw material: when 
particle size is decreased to nanosized area, the intrinsic properties like solubility are altered as compared 
to bulk sized drug powders. The overall benefits connected to small particle size can be divided into three 
main categories: i) fast dissolution, ii) increased solubility, and iii) better adhesion to membranes. However, 
absolutely most important effect reached with drug nanocrystals is faster dissolution rate based on the 
large surface area per mass solid. But, the role of stabilizer and its careful selection should not be 
neglected. The main role of stabilizer is to stabilize inherently unstable drug nanoparticles against 
aggregation and/or Ostwald ripening after the production and during the storage of nanocrystalline 
formulations. However, many stabilizers utilized can for example help in maintaining the supersaturated 
state in vivo reached after fast dissolution of nanocrystals or they may perform as permeation enhancers 
(Gao et al., 2012; Gao et al., 2014; Chen and Li, 2015; Ueda et al., 2015).  
There are excellent earlier reviews related to drug nanocrystals (Müller et al., 2001; Keck and Müller, 2006; 
Junghanns and Müller, 2008; Müller et al., 2011a; Müller and Keck, 2012; Möschwitzer, 2013; Brochard, 
2016; Li et al., 2016). However, often the role of higher saturation solubility and utilization of 
supersaturation reached with nanocrystalline formulations are poorly described. This review exposes 
various aspects of drug nanocrystals from all the aspects of basic physicochemical principles to final 
bioavailability in an integrated fashion. The fast dissolution and increased solubility reached with drug 
nanocrystals are discussed in detail starting from the physicochemical principles behind drug nanocrystals 
and ending on formulation examples visioning the broader scope.  
1 Characteristics of drug nanocrystals 
Drug nanocrystals are solid drug particles surrounded by a layer of stabilizer(s), and sometimes the drug 
nanocrystals have also been named as solid micelles. Small particle size of hundreds of nanometers makes 
the nanocrystals unstable and stabilizer(s) are needed to prevent the aggregation of individual nanosized 
particles. Typical stabilizers are different kind of polymers, like cellulose derivatives, PVP, poloxamers, 
vitamin E TPGS  (Guo et al., 2013; Tuomela et al., 2014; Rahim et al., 2017) or amphiphilic surfactants such 
as polysorbates, SDS (Liu et al., 2011; Rahim et al., 2017), and these can also improve the solubility via 
better wetting and solubilizing effects.    
1.1 Increased dissolution rate 
Increased dissolution rate as compared to bulk drug is the most important effect reached with drug 
nanocrystals, and it is based mainly on large interfacial area due to the decreased particle size. Taken as an 
example spherical particles, the surface area versus volume, A/V = 3/r. This means that if the particle size is 
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reduced from 50 µm (typical particle size for bulk drug) to 500 nm (drug nanocrystals), increase in 
dissolution rate is 100 fold according to Noyes-Whitney equation (Equation 1): 
𝑑𝐶
𝑑𝑡
=
𝐷𝑆
𝑉ℎ
(𝐶𝑆 − 𝐶) ,  (1) 
where dC/dt is dissolution rate (concentration change as a function of time), D is diffusion coefficient, S is 
surface area, V is dissolution volume, h is diffusion layer thickness, Cs is saturation concentration and C is 
the concentration at time t. Accordingly, particle size is an important factor for determination of dissolution 
rate. However, when the dissolution tests are performed under sink conditions, the differences are typically 
not seen between different nanocrystal size fractions, and more discriminating dissolution test protocols 
are needed (Liu et al., 2013). 
1.2 Higher saturation solubility 
In Noyes-Whitney equation diffusion layer thickness and saturation concentration are also affected by the 
nanosized particles. For particle size below approximately 50 µm the diffusion layer is starting to get 
thinner (Sheng et al., 2007), which enhances the dissolution. The increase in saturation concentration is 
stated in the Ostwald-Freundlich theory (Equation 2), which was first developed for liquid droplets in gas 
phase, but later it has been shown to be correct also for solid particles in liquid below particle sizes 
approximately 1 µm:  
𝑆𝑁𝑃 = 𝑆0 (
2𝑉𝑚𝛾
𝑅𝑇𝑟
),   (2) 
where SNP is the solubility of nanoparticles with a radius r, S0 is the solubility of bulk material, Vm is the molar 
volume, γ is the interfacial tension, R is the gas constant and T is the temperature. The effect of particle size 
on saturation concentration starts to be seen with particle sizes below 1 µm, but when the particle size is 
decreased the effect is more pronounced; below 100 nm the increase is even exponential. 
Higher dissolution rate and increased saturation concentration leads to supersaturated state, which has 
been shown to enhance drug permeation (Brouwers et al., 2007 and 2009; Mellaerts et al., 2008). The 
challenge in vivo is the maintenance of supersaturation until the permeation takes place and hindrance of 
uncontrolled precipitation/crystallization.  
1.3 Supersaturated state 
Similar to amorphous formulation, due to the higher apparent solubility of drug nanocrystals as compared 
to thermodynamic solubility, drug nanocrystals produce supersaturated state, which is thermodynamically 
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unstable (Mah et al., 2015). For example, when drug nanocrystals were compressed to a flat surface, the 
concentration levels of the dissolved drug next to the sample surface with nanocrystals sized 580 nm was 
over five-fold higher than concentration levels reached with bulk indomethacin (Figure 1; Sarnes et al., 
2013). In another study, aqueous solubility values of nimodipine nanocrystals were determined by a 
traditional shake flask test (Fu et al., 2013). When the aqueous solubility of crude drug after 72 hours 
testing was 1.879 µg/ml, for nanocrystals with average particle size of 830 nm, 500 nm and 160 nm, 
corresponding solubility values were 22.526 µg/ml, 30.093 µg/ml and 51.269 µg/ml, respectively, indicating 
very high level of supersaturation and also considerably long time period for the system to remain in 
supersaturated state. Sun et al. (2012) tested kinetic solubility values of nanocrystalline coenzyme Q10 with 
particle size fractions from 80 nm to 700 nm, and the kinetic solubility increased as the particle size 
decreased. Ueda et al. (2015) analyzed the maintenance of supersaturated state with amorphous and 
nanocrystalline carbamazepine by real-time NMR spectroscopy by monitoring the amount of dissolved 
carbamazepine. With carbamazepine nanocrystals concentration values were nearly constant for 50 h time, 
while with amorphous carbamazepine the initial concentration was higher but it then dropped below the 
concentration of the nanocrystal sample.  Accordingly, examples of higher apparent solubility values 
related to nanocrystals can be found, but still this clear benefit reach with nanocrystals are mostly left 
without consideration in nanocrystal applications. 
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Figure 1. Apparent concentration-distance profiles from UV imaging of indomethacin nanocrystals (particle 
size 580 nm) and micron sized particles with two different stabilizers (poloxamers F68 and F127) as well as 
bulk indomethacin at 5, 15 and 30 min time points: (A) F68 stabilized nanocrystals, (B) F68 stabilized micron 
sized particles, (C) F127 stabilized nanocrystals, (D) F127 stabilized micron sized particles and (E) bulk 
indomethacin. (Reprinted from Sarnes et al., 2013 with permission from Elsevier). 
The challenge in benefitting supersaturation is how to maintain it until the successful drug permeation. For 
example, in GI tract the pH changes may induce fast precipitation, like was the case with itraconazole 
nanocrystals produced by wet milling (Sarnes et al., 2014). Dried nanocrystals were packed in capsules, and 
in vivo tests were performed with rats. Though in vitro itraconazole nanocrystals showed superior 
dissolution rate as compared to Sporanox® granules, the in vivo bioavailability was higher with marketed 
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product. The problem with drug nanocrystals was that fast dissolution was followed by rapid transition of 
drug solution to intestine, where precipitation of itraconazole took place: as a basic compound, the 
solubility of itraconazole is appr. 250-times higher in stomach (lower pH) as compared to intestine (higher 
pH). However, when itraconazole nanocrystals were bind to nanofibrillar cellulose matrix, increased 
dissolution rate in vitro was also seen in enhanced in vivo performance of the drug: AUC-value with 
nanocrystalline formulation was 1.3 times higher as compared to marketed Sporanox® granules (Figure 2; 
Valo et al., 2011). Accordingly, the formulation was in key role in order to reach IVIVC. 
 
Figure 2. Plasma concentration profiles of itraconazole and OH-itraconazole in rats after oral administration 
of Sporanox® granules, three nanocrystalline formulations (HFBI, HFBI + NFC, HFBI-DCBD + NFC) and 
itraconazole microsuspension. (Reprinted from Valo et al., 2011, with permission from Elsevier.) 
Another formulation factor, which should be taken into account is selection of stabilizer for drug 
nanocrystals. As already discussed, dissolution from drug nanocrystals can lead to supersaturated state. 
Also, it is well known that some polymers, like hydroxypropyl methylcellulose (HPMC), hydroxypropyl 
methylcellulose acetate succinate (HPMCAS), poly(vinyl pyrrolidone) (PVP), and Soluplus®, are able to 
prohibit drug crystallization from supersaturated solutions and hence capable of maintaining the system in 
highly concentrated state (Van Speybroeck et al., 2010; Chauhan et al., 2014; Ueda et al., 2014; Surwase et 
al., 2015, Figure 3); molecular level interactions between the polymer and the drug has been shown to 
determine the efficiency of maintaining the level of supersaturation (Chauhan et al., 2014; Ueda et al., 
2014). Same above mentioned polymers has been utilized also as stabilizers for drug nanocrystals (Tuomela 
et al., 2014). In our preliminary studies we have shown same kind of crystallization prohibiting effect of 
HPMC and PVP in nanocrystalline systems (unpublished data), but with nanocrystals the impact of polymers 
still needs more studies in order to fully utilize the benefits of these polymers properly. 
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Figure 3. Impact of PVP on maintaining the supersaturated state of amorphous indomethacin for 
indomethacin-PVP solid dispersion (Figures a,c,e) and for amorphous indomethacin dissolved in aqueous 
PVP solution (Figures b, d, f) in pH 5.5 at 25 °C. Figures a and b: PCA scores plots of the IR spectra of 
indomethacin samples (arrows indicating the path of crystallization); Figures c and d: IR spectras of 
indomethacin samples; and Figure e and f: concentration-time profiles showing the maintenance of 
supersaturated state in the presence of PVP. (Reprinted from Surwase et al., 2015 with permission from 
Elsevier.) 
2 Formation of drug nanocrystals 
There are two approaches to make drug nanocrystals: i) top-down approach, where nanosized particles are 
produced by decreasing the particle size of bulk drug in a liquid suspension, for example by different kinds of 
milling or homogenization techniques (Keck and Müller, 2006; Peltonen and Hirvonen, 2010; Laaksonen et 
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al., 2011; Müller et al., 2011b; Möschwitzer, 2013), and ii) bottom-up approach, where the nanosized 
particles are built molecule by molecule by precipitation (Valo et al., 2011 and 2013; Wang et al. 2012). Most 
of the commercial pharmaceutical products are produced by top-down methods, mostly by milling, because 
in these techniques the process repeatability is at a high level and changes in scaling are considerably easy 
to perform (Chin et al., 2014). Process yield varies depending on the process and process type, and in the 
literature there are not many reports related to process yield. For example, liquid atomization based 
processes the yield can be very low, and material is lost on the atomization chamber walls. In milling 
processes, if the process is batch process, the yield can be considerably high, but again, material can be lost 
on the surfaces of the beads and the vessel.  
2.1 Physical properties of drug nanocrystals 
All the production techniques produce solid drug cores surrounded by a stabilizer layer, but depending on 
the process, certain properties, like particle shape, size, porosity and level of crystallinity, may be altered 
depending on the selected process and process parameters. Selection of stabilizer should be based on the 
drug properties, but it is also good to be aware of that many common stabilizers have some drug transport 
influencing activities. For example, many surfactants, like polysorbates, are able to open up tight junctions 
(Deli, 2009) and poloxamers and polysorbates are known to have effects on intestinal P-gp activity (Thakkar 
and Desai, 2015).  
When thinking about the particle shape, milling for example typically produces edged particle shapes (Liu et 
al., 2011), while antisolvent precipitation or liquid atomization can lead to almost spherical particles (Valo et 
al., 2011). Also the raw material affects the particle shape: milling of itraconazole produced needle shaped 
particles while indomethacin formed oval particles (Liu et al., 2011). In the bottom-up techniques particle 
sizes below 100 nm are easily reached (Valo et al., 2011), but also modern high energy milling set-ups can 
lead to particle size fractions around 100 nm (Bujnakova et al., 2015a and 2015b; Li et al., 2015). More porous 
particles can be formed with liquid atomization based techniques, and with these techniques also amorphous 
material can be produced (Wang et al., 2012). Formation of amorphous material increases the solubility, but 
it also creates stability problems where uncontrolled crystallization is possible.  
2.2 Quality by Design (QbD) approach for production of drug nanocrystals 
All the listed properties are important to be aware of and to control because they can have an impact on 
dissolution, solubility and also cellular interactions in vivo (Liu et al., 2013; Ma et al., 2013; Sarnes et al., 2013; 
Shang et al., 2014), especially, when thinking of Quality by Design (QbD) approach for production of 
nanosuspensions (Ghosh et al., 2012; Peltonen and Strachan, 2015; Kassem et al., 2017; Li et al., 2017; 
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Soliman et al., 2017). QbD approach for nanosuspension production can be divided into three phases: i) 
selection of stabilizer(s) and production method based on Quality Target Product Profile (QTPP), ii) 
establishing Critical Quality Attributes (CQAs), and iii) formation of a design space based on Design of 
Experiments (DoE) (Li et al., 2017). CQAs can be for example particle size, shape, solubility or stability 
(Peltonen and Strachan, 2015). Critical process parameters (CPPs) aid in process controlling in order to find 
suitable tools for process control purposes during manufacturing, while proper design space ensures 
repeatable product performance batch after batch. For example, Afolabi et al. (2014) studied with the aid of 
microhydrodynamic model the effect of stirrer speed, bead concentration and drug loading on the bead-
bead collisions and particle breakage kinetics during the wet milling process. They found out that increase in 
stirrer speed or bead concentration led to faster breakage via higher specific energy and milling intensity 
factor while increase in drug loading had opposite effect. 
2.3 Down-scaling and up-scaling of nanocrystallization processes 
Up-scaling and down-scaling are possible with some nanocrystallization techniques and mostly they have 
been studied with milling setups (Van Eerdenbrugh et al., 2009; Singare et al., 2010; Niwa et al., 2011; Ghosh 
et al., 2012; Tuomela et al., 2015). In milling aqueous drug-stabilizer suspension together with milling 
medium is agitated and scaling changes are considerably easy to perform. The total energy input and particle 
size reduction kinetics determine the final particle properties, and this can cause differences in final product 
properties (Date and Patravale, 2004; Bilgili and Afolabi, 2012; Afolabi et al., 2014; Tuomela et al., 2015). 
Yuminoki et al. (2016) used rotation/revolution mixer for media milling (Takatsuka et al., 2009; Yuminoki et 
al., 2016). The smallest batches were 100 mg of drug material. Later, process was scaled up to 1 kg batch 
size. Specific collisional energy was calculated by a theoretical equation modified for wet milling. Calculations 
showed that the relative centrifugal acceleration of revolution (straightly related to radius of the revolution 
and the number of revolutions per minutes) and drug concentration in the suspension where most important 
process variables: when these factors where identical, different scaling produced similar particle size 
fractions. Other successful scaling up case examples are: SmartCrystal combination process from laboratory 
to pilot scale (Shaal et al., 2010), combination process with static mixing and spray drying to continuous large-
scale production (Hu et a., 2011), and precipitation followed by homogenization for large scale production 
(Quan et al., 2011). 
Van Eerdenbrugh et al. (2008) performed milling in 96-well plate with 10 mg of drug: in screening tests the 
drug amount is enough for a thorough physicochemical characterization. Seven drugs were milled 
successfully, when the drug suspension together with milling pearls were put into the wells and the 96-well 
plate was agitated in an orbital shaker. Instead of milling particle breakage can be reached via acoustic mixing 
(Leung et al., 2014). In this technique, the drug suspension together with milling pearls are mixed in an 
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acoustic mixer. For screening purposes, the mixing can be performed in 96-well plate with only 2 mg of drug 
per well. Still another possibility is to put the suspension together with the milling pearls into small vials, 
which are packed inside of milling vessel. All the above mentioned protocols are suitable for preclinical 
screening purposes, but extra care should be taken with wearing of the well plate/vials, which leads 
contamination. In milling it is important that the milling pearls and vessel are from the same material, and 
softer well plate/vial material are vulnerable for erosion during milling process as well.  
During high pressure homogenization, suspension is forced through a narrow homogenization gap, which 
limits the scaling down possibilities. However, equipment with 3.5 ml sample volume has been tested (Müller 
et al., 2001), and in laboratory scale the equipment can be used in discontinuos mode, which lowers the 
required sample amount (Grau et al., 2000). 
2.4 Top-down nanocrystallization techniques 
In top-down methods the particle size diminishing is based on mechanical attrition or high pressure collisions, 
and these can induce contamination due to the wearing and tearing of the equipment (Juhnke et al., 2012; 
Li et al., 2015). Process parameters like bead size/bead material, stirrer speed and energy input affect the 
level of contamination. With the same bead material, level of contamination can be minimized by shortening 
the process time and lowering the bead contact pressure by using smaller bead sizes.  Other drawbacks of 
the top-down techniques are high energy consumption, particularly if the process times are long; however, 
today especially in milling the process times can be considerably shorter due to the more efficient milling 
equipment which lowers the overall energy consumption (Liu et al., 2011). 
Milling and high pressure homogenization are performed in suspension. Mostly the suspension medium is 
water, but also oils or PEGs can be used (Keck and Müller, 2006; Al-Kassas et al., 2017). Possibility to avoid 
organic solvents has made these techniques environmental friendly (Chin et al., 2014; Peltonen et al., 2014). 
Presence of water also protects the contents against formation of amorphous material, because water 
enhances molecular mobility and lowers the glass transition temperature (Sharma et al., 2009). After milling 
the drug is typically in crystal form, although polymorphic changes are possible (Müller et al., 2001; Liu et al., 
2011). High pressure homogenization may induce lowering of crystallinity, but also here the presence of 
water stabilizes the drug crystals (Müller et al., 2001; Sharma et al., 2009; Homayouni et al., 2014; Soliman 
et al., 2017).  
Technically high pressure homogenization (HPH) can be separated in two different approaches: i) jet 
streaming (microfluidizer, IDD-PTM, insoluble drug delivery microparticle technology) and ii) piston-gap 
homogenization. In jet streaming high energy suspension flows collide in a microfluidizer, while in piston-gap 
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type homogenizer drug suspension is forced with high pressure through a narrow gap (Keck and Müller, 
2006). Piston gap homogenization can further be divided in homogenization in water (Dissocubes®) (Müller 
et al., 2011a) and in non-aqueous media, like PEG (Nanopure®) (Radtke and Müller, 2001; Salazar et al., 2014). 
2.5 Bottom-up nanocrystallization techniques 
In bottom-up processes the drug nanocrystals are formed via precipitation/crystallization from a 
supersaturated solution. Bottom-up techniques have been studied a lot in laboratory scale, but scaling up is 
often problematic. Challenges are faced also due to difficulties in controlling the particle size growing, finding 
a suitable solvent/antisolvent combination, and the volume and demanding removing process of solvents. 
Especially solvent/antisolvent process mostly requires utilization of organic solvents due to poor solubility 
properties of drug materials.  
Most traditional way is to induce precipitation via antisolvent addition, but also supercritical fluids, solvent 
removal or liquid atomization based techniques have been used (Valo et al., 2011; Sinha et al., 2013a; Valo 
et al., 2013; Sahu and Das, 2014). Especially liquid atomization techniques may produce amorphous materials 
due to the extremely fast solvent removal process, which can cause stability problems afterwards when 
amorphous drug starts to crystallize (Sinha et al., 2013a; Homayouni et al., 2014; Soliman et al., 2017). 
2.6 Combination nanocrystallization methods 
If the end product is not reaching the required CQAs in a single process, combination techniques can be 
utilized. Combination techniques are two step processes, which include i) pre-process step, for example pre-
milling or precipitation and ii) high-energy top-down process (most often milling or high pressure 
homogenization) (Sinha et al., 2013b; Zong et al., 2017). Benefits of combination methods are that with them 
often even smaller particle sizes can be reached and avoidance of process related problems, like clogging of 
high pressure homogenizer, or shortening of the final top-down process time.  
Though combination techniques can be beneficial when thinking of the end product properties or in avoiding 
process related challenges, more complicated process increases overall costs and complexity of the whole 
production process. Hence, combination techniques are never the first choice, and they should be selected 
only if clear benefits are reached by utilizing them. 
First combination technique was antisolvent precipitation pre-process followed by high pressure 
homogenization (NanoedgeTM; Möschwitzer, 2003). More recent are SmartCrystal® group of technologies 
where high pressure homogenization is combined with different pre-processes (Shegokar and Müller, 2010): 
H42 (spray-drying pre-process), H69 (precipitation pre-process), H96 (lyophilization pre-process) and CT 
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(media milling pre-process). More rarely studied combinations are for example antisolvent precipitation 
combined with ultrasonication (Soliman et al., 2017).  
3 Drug nanocrystal based formulations 
Nanocrystal formulations for drug delivery purposes have been increasingly popular in recent years (Lakshmi 
and Kumar, 2010; Arunkumar et al., 2009). As stated above in this review article, current drug discovery 
programs provide a high number of drug candidates showing high in vitro efficiencies, but actual clinical 
applications have often been restricted due to the poor aqueous solubility. Nanocrystals provide a potential 
way to overcome this problem and, thus, several successful, mostly orally administered products have 
already reached the market or are in the research pipelines (Junghanns and Müller 2008, Bansal et al., 2012; 
Table 1). Due to the increased surface area a rapid in vivo dissolution, fast absorption and increased 
bioavailability of these kinds of drugs have been reached. Administration of drug nanocrystals may take place 
via different drug delivery routes. Oral drug delivery route is the most popular and convenient and oral solid 
dosage forms of nanocrystals are usually preferred for commercialization. Sirolimus (Rapamune®) was the 
first nanocrystalline drug on the market in 2000, soon followed by other orally administered nanocrystalline 
formulations like megestrol acetate (Megace®, 2001), aprepitant (Emend®, 2003) and fenofibrate (Tricor®, 
2004) (Bobo et al., 2016).  
Table I. Examples of nanocrystalline products on the market approved by the US FDA. 
Modified from Bobo et al. (2016) and Gao et al. (2013). 
   
Drug Indication Special notes Process 
  
Aprepitant Antiemetic Faster absorption and higher bioavailability Milling 
  
Fenofibrate Hyperlipidemia Higher bioavailability, easier administration Milling 
  
Sirolimus Immunosupressant Higher bioavailability Milling 
  
Megestrol acetate Anti-anorexic Reduced dosing Milling 
  
Morphine sulfate Psychostimulant Higher drug loading and bioavailability, extended release Milling 
  
Dexamethyl-phenidate HCl Psychostimulant Higher drug loading and bioavailability Milling 
  
Methylphyenidate HCl Psychostimulant Higher drug loading and bioavailability Milling 
  
Tizanidine HCl Muscle relaxant Higher drug loading and bioavailability Milling 
  
Calcium phosphate Bone substitute Mimics bone structure allowing cell adhesion and growth NanOssTM  
  
Palperidone palmitate Schizophrenia Allows slow release of injectable low solubility drug Milling, HPH 
  
Drug development in mind, the size-controlled nanocrystals of a drug under development are often 
converted into dry powders, which are further formulated into dosage forms: tablets, capsules, pellets or 
liquid nanocrystal suspensions. Gao et al. (2012) listed the benefits of nanocrystalline and nanoparticulate 
dosage forms in oral drug delivery: enhanced oral bioavailability due to the improved drug 
dissolution/solubility, reduced fasted/fed state variation in drug absorption, potentially improved 
transcellular uptake or prolonged mucoadhesion of the nanoparticles, and improved safety profiles of the 
nanocrystal formulations. The mucoadhesive and gastroretentive properties of coated (stability-improved) 
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nanoparticles can be modified, for example, with hydrophobin proteins (Sarparanta et al., 2012). Upon entry 
of the nanoparticles from the stomach into the intestines, it was observed that hydrophobin-protein coated 
nanoparticles were retained in rat stomach up to three hours after administration, whereas corresponding 
uncoated nanoparticles were released significantly faster in the same conditions.  
Despite the benefits above and the relative ease of administration, nanocrystals provide special challenges 
in the design of oral solid drug formulations. Tuomela et al. (2015) screened comprehensively powder and 
tablet compositions of indomethacin and itraconazole nanocrystals in order to find out optimal properties 
for the tableting conditions and tablet formulations. As such, the mere presence of nanocrystals in the 
composition improved the compressibility of tablets. The smaller the particle size was, the more contact 
surfaces there were providing potential inter-particle bonds that resulted in increased hardness/crushing 
strength of the tablets. When the nanocrystals were processed into granules before tableting, a further 
decrease in the required compression force was detected (Tuomela et al., 2015). Disintegration testing of the 
tablets revealed changes in the texture and inner structures of the tablets: the less was the amount of drug 
nanocrystals in the formulation, the more porous was the structure formed. Disintegration times correlated 
also well with the crushing strength values of the tablets. Composition-wise, it was found out, at least in the 
cases of indomethacin and itraconazole, that the optimal amount of freeze-dried nanocrystals in the tablet 
composition was about 40% of the total mass  (corresponding to theoretical drug loading of 22-29%), in which 
cases the improved dissolution profiles and disintegration times of the corresponding nanocrystal tablets 
were still maintained. 
After oral delivery, development of parenterally administered nanocrystal formulations is the second most 
popular approach. Intravenous, intramuscular and subcutaneous delivery routes provide a quick (i.v.) or 
potentially retarded (i.m.) onset of action, rapid reach of different body parts and organs with concomitant 
potential for drug targeting, and reduced dosage need of the drug. These routes are beneficial for drugs 
undergoing first-pass metabolism and drugs that are not absorbed or are degraded/irritating in the GI tract. 
Nanoparticles have potential as novel intravascular formulations for both diagnostic (imaging) and 
therapeutic purposes (drug delivery), or even combination of these (theranostics) (Ahmed et al., 2012). 
Successful parenteral nanoformulation delivery requests the drug to be able to target in specific tissues and 
cell types and escape from the reticuloendothelial system (Åkerman et al., 2002). Parenteral administration 
of nanocrystals has certain advantages: administration of poorly soluble drugs without using high 
concentrations of toxic co-solvents, improved therapeutic effect of the drug, and targeted drug delivery to 
macrophages. Obvious drawback of this delivery route is the invasiveness of the mode of administration and 
the associated poor patient compliance.  
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Fuhrmann et al. (2014) discuss thoroughly the benefits and difficulties in the in vitro - in vivo correlation of 
injectable, non-targeted and targeted nanocrystals. As small (< 400 nm) and adjustable systems, the 
intravenously injected nanocrystals are able to extravasate from the blood through the leaky endothelium 
and accumulate in, for example, tumor tissue via the enhanced permeation and retention (EPR) effect 
(Matsumura and Maeda, 1986). In addition to this passive targeting phenomenon, some of the stabilizers 
can be functionalized with targeting/internalizing ligands to promote active tumor accumulation or uptake, 
respectively. These vital stabilizers, for example polymers or surfactants, typically stabilize nanocrystals by 
adsorbing to the surfaces and provide steric (e.g., poloxamers, cellulose derivatives) or electrostatic (e.g., 
sodium dodecyl sulfate, Tween®) barriers to aggregation (Peltonen and Hirvonen, 2008; Fuhrmann et al., 
2014). As only a small amount of stabilizing agent is typically required to mask the nanocrystals and prevent 
their aggregation, drug contents of typically 50 to 90% (wt) are reached, which is clearly higher than with 
some other nanocarrier systems. As described in more detail in this review, nanocrystals exhibit a 
characteristic nonlinear increase of kinetic solubility upon miniaturization that is described by the Ostwald–
Freundlich equation (Chapter 1.2). This increased rate of dissolution is generally utilized for the non-targeted 
delivery. A drawback in targeted i.v. nanocrystal delivery is that the enhanced dissolution interferes and 
reduces the efficacy of targeted nanocrystalline drug delivery: increased drug delivery off the target, reduced 
circulation time of the nanosystems, and potential sub-standard efficacy and utilization of the stabilizing 
agents and/or targeting agents. 
3.1 Development of nanocrystalline cancer drug formulations 
In order to increase the cancer drug deposition in cancerous tissues, the research group of Professor Leroux, 
among others, has applied different strategies for nanocrystals delivery and action: instead of utilizing the 
fast and high dissolution, they have intensively tested polymer-coated paclitaxel nanocrystals with slow 
dissolution and retarded drug release properties (Polomska et al., 2017). Successful delivery of the drug to 
the site of disease requests that the nanocrystals should deposit a signiﬁcant amount of the cancer drug to 
the right place in order to improve the treatment efﬁcacy, although at the same time the formulation should 
minimize the potential drug-associated, and also the excipient-associated, side effects. In this respect the 
small size and high-energy nanocrystals surfaces lead to a too rapid dissolution and administration, which 
may oftentimes reduce the local accumulation of the drug at the exact sites of cancerous tissue(s). In the 
case of paclitaxel nanoparticles, this might lead to markedly higher risk of hypersensitivity reactions and 
higher incidence of neuroptenia. Attempts to extend and prolong the delivery and improve the relatively low 
accumulation of anticancer drug nanocrystals has been tested by polyelectrolyte multilayers (layer-by-layer 
technology; Polomska et al., 2017), by PEGylated nanocages as non-sheddable stabilizers for drug 
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nanocrystals (Fuhrmann et al., 2012), and by redox-responsive stabilizers for drug nanocrystals (Fuhrmann 
et al., 2013). 
Also other groups have studied the extended and targeted delivery of the cancer drug paclitaxel. Deng et al. 
(2010) studied the stabilization method on paclitaxel-Pluronic F127 nanocrystals (Figure 4). Increased drug 
dosing was expected to result in improved antitumor activity of paclitaxel without the incidence of acute 
toxicity. Desorption experiments of Pluronic F127 stabilizer showed different surfactant adsorption affinities 
to the paclitaxel nanocrystal surfaces above and below the critical micelle concentration (CMC) of the 
polymer. Below the CMC the monomers were bound to the nanocrystal surface with high affinity, but above 
the CMC the low affinity surfactant aggregates were removed rapidly from the nanocrystal surfaces upon 
dilution. The overall conclusion in this study was that in order to improve the stability of nanocrystals, re-
nanonization by incubation–sonication procedure should be used to disrupt the preferred crystal growth 
patterns of paclitaxel (Deng et al., 2010).  
 
Figure 4. TEM figures of F127 stabilized paclitaxel nanocrystals. Drug surfactant ratio (A) drug:surfactant ratio 
1:10 (w/w) and (B) 1:20 (w/w). Scale bar is 200 nm. (Reprinted from Deng et al., 2010 with permission from 
Elsevier). 
Lu et al. (2014) prepared and evaluated paclitaxel nanocrystal formulations by stabilizing them non-
covalently with a serum protein transferrin. In addition to transferrin, also other serum proteins including 
albumin and immunoglobulin G were evaluated with respect to the stabilizing effect. In vivo antitumor 
efficacy studies were conducted in mice that had been inoculated with drug containing KB cells. The results 
demonstrated significantly higher tumor inhibition rate (45%) for the paclitaxel-transferrin formulation 
compared to the paclitaxel nanocrystal treatment alone (29% inhibition) (Figure 5). It is to be noted here that 
commercial Taxol® formulation showed higher antitumor activity in mice than the paclitaxel-transferrin study 
formulations, reaching a 93% tumor inhibition rate (Lu et al., 2014). On the other hand, the paclitaxel-
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transferrin formulations showed lower levels of toxicity, which was indicated by a steady increase in body 
weight of the mice during the cancer treatment period. In comparison, treatment with Taxol® resulted in 
toxicity related problems as the body weight of the mice was decreased.  
 
Figure 5. In vivo antitumor efficacy of paclitaxel formulations in mice: curves from top to down: Control, PTX 
paclitaxel nanocrystal suspension, PTX-Trf paclitaxel transferrin nanocrystal suspension and Taxol®. 
(Reprinted from Lu et al., 2014 with permission from Elsevier). 
Professor Torchilin’s group prepared stable nanocrystal colloids of poorly soluble cancer drugs paclitaxel and 
tamoxifen with very high drug loadings (up to 90% wt) utilizing the layer-by-layer technology, alternating the 
adsorption of oppositely charged polyelectrolytes on the surface of drug nanocrystals produced by 
ultrasonication of larger drug crystals (Agarwal et al., 2008). Such polymeric coatings prevent the aggregation 
of drug nanocrystals and create stable polymeric shells on their surface. Drug release rates of the cancer drug 
nanocrystals can be controlled by assembling multilayer shells with variable shell densities and thicknesses. 
Also here various specific targeting ligands could be rather easily attached to the surfaces of the nanosystems 
by using polymers with free reactive groups on the outer coating, e.g., free amino groups. Shutava et al. 
(2012) prepared 150-200 nm nanocapsules containing 60–70% (wt) of poorly soluble paclitaxel and 
camptothecin, again with the layer-by-layer assembly of the drug nanocores, in solutions containing 
uncharged stabilizers. Concentrated colloids of the cancer drugs (3-5 mg/mL) were found out to remain stable 
in isotonic salt buffers. Nanocrystal aggregation during the layer-by-layer-assembly was prevented by using 
minimal amounts of low molecular weight block-copolymers of poly-L-lysine and poly-L-glutamic acid with 
polyethylene glycol (PEG) in combination with heparin and bovine serum albumin at each bilayer building 
step. The PEGylated nanosystems presented high colloidal stability in PBS buffer and increased protein 
adhesion resistance. 
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SN-38 (7-Ethyl-10-hydroxycamptothecin) is another potent broad-spectrum antitumor drug, an irinotecan 
derivative. As the compound is poorly soluble and instable (with a labile active lactone ring), the clinical use 
of this compound has been compromised. Nanocrystal formulations have, therefore, been attempted to 
solve these problems and evaluate the true antitumor effect of SN-38 in vitro and in vivo (Chen et al., 2017).  
Nanocrystals with clearly different particle sizes were prepared, SN-38/NCs-A and SN-38/NCs-B, with mean 
diameters of 230 and 800 nm, respectively. Dissolution and release rate results in the case of SN-38/NCs-A 
were significantly faster than with SN-38/NCs-B. Accordingly, enhanced intracellular accumulation of SN-
38/NCs-A was observed in HT1080 cells compared to that of SN-38/NCs-B nanocrystals and SN-38 solution. 
Moreover, the SN-38/NCs-A nanocrystals provided a higher bioavailability and significant inhibition of tumor 
growth compared to the SN-38 solution and SN-38/NCs-B nanocrystals in vivo after intravenous injection 
(Chen et al., 2017). The tissue distribution study in tumor-bearing mice showed that the nanocrystals could 
markedly improve the drug accumulation in tumor tissues by, presumably, the EPR effect when compared to 
SN-38 solution. The amount of SN-38 in tumors of after the treatment with SN-38/NCs-A nanocrystals was 
clearly higher than after the delivery of SN-38/NCs-B nanocrystals.  
As stated repeatedly above, one interesting way to slow down the dissolution and improve the (targeted) 
delivery of anticancer nanocrystals is the utilization of layer-by-layer assemblies of polyelectrolytes around 
the nanocrystals. As shown in the above study examples, this has been proven to be a successful strategy at 
least in vitro. However, in vivo nanoparticles with charged surfaces are highly susceptible to opsonization and 
clearance by the mononuclear phagocyte system, leading to short biological half-lives and fast accumulation 
in the liver and spleen (Sarparanta et al., 2012). This fast clearance obviously diminishes significantly the 
tumor accumulation of “normal” nanocrystals in vivo. Flexible hydrophilic polymers like poly(ethylene glycol) 
on top of the multilayers are thus warranted in order to sterically hinder the adsorption of plasma proteins 
on the nanosystems (Polomska et al., 2017). As of today, little is still known about the stability of PEGylated 
polyelectrolyte-coated drug nanocrystals in the complex environment of blood circulation and tissue 
compartments, and also about the circulation times or drug biodistribution proﬁles of these nanosystems in 
vivo. 
3.2 Orally administered nanocrystal formulations 
Despite the numerous success stories (Table 1), formulation and delivery of nanocrystalline dispersions, 
tablets and other solid formulations via the GI-tract are often not straightforward processes (Gao et al., 
2012). The impact of physiological factors like the variation of pH and peristalsis towards the nanocrystals 
are not simple to predict.  The acidic nature of a drug affects strongly to the rate and extent of nanocrystal 
dissolution in the GIT. For example, in the cases of indomethacin and itraconazole the fast in vitro dissolution 
may not be maintained in the gut/intestines in vivo, leading to potentially uncontrolled drug precipitation 
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during the transit in the GI-tract (Sarnes et al., 2014, Figure 6). In the GI fluids, the disintegration of the 
nanoformulation leads to the formation of nanocrystal dispersion. Stabilizer molecules attached on the 
surface of nanocrystals will offer again ionic or steric repulsion, given that they are not affected by the 
gut/intestines environments (Peltonen and Hirvonen, 2008). Just like with the injectable nanocrystal 
formulations, the most orally relevant nanocrystal stabilizers are found in the groups of polymeric and non-
ionic surfactants, such as poloxamers or polysorbate (Tween®) 80, as these stabilizers provide effective steric 
repulsion in GI fluids, given that the amount of stabilizers is adequate (Lai et al., 2014). Generally, again, ionic 
stabilizers like NaCMC and SDS, are effective in aqueous environment, but often the ionized state is not 
maintained in dry nanocrystalline powder material, thus making them less effective. Furthermore, ionic 
stabilizers are sensitive to pH changes and ionic strength when the dry powders are redispersed in the GI 
fluids. 
 
Figure 6. Bioavailability in rats of itraconazole and OH-itraconazole after per oral administration of 
nanocrystalline itraconazole formulations: nanocrystal suspension (ITC-NPs), freeze dried nanocrystals 
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(freeze dried ITC-NPs), granulated nanocrystals (granulated ITC-NPs), Sporanox® granules and physical 
mixture (mean ± sem, n = 5–6). (Reprinted from Sarnes et al., 2014 with permission from Elsevier). 
Rahim et al. (2017) attempted to enhance the dissolution rate, oral bioavailability and analgesic potential of 
aceclofenac nanocrystals in Swiss albino rabbits. The nanocrystal suspensions were produced by a 
precipitation–ultrasonication method with hydroxypropyl methylcellulose, polyvinylpyrrolidone and sodium 
dodecyl sulfate as stabilizers/excipients. Saturation solubility of aceclofenac nanocrystals was increased 2.6- 
and 4.5-fold compared with unprocessed API in stabilizer solution and with totally unprocessed drug, 
respectively. As expected, the dissolution rate of the aceclofenac nanocrystals was substantially enhanced in 
vitro, and also the in vivo studies of stabilized aceclofenac nanocrystal suspension showed increased Cmax 
(4.98- and 2.80-fold) and AUC0→24 h (3.88- and 2.10-fold) values of the nanocrystal formulations when 
compared with the unprocessed drug and the currently marketed formulation of aceclofenac, respectively. 
The improved antinociceptive (pain receptor relieving) activity of the aceclofenac nanocrystals was also 
shown at lower drug doses. The same group (Shah et al., 2016) developed nanocrystalline formulations of 
antimalarial drug artemether, another compound of poor solubility and consequently low bioavailability. 
“Smart nanocrystals” of artemether were produced using a wet milling technology resulting in mean 
artemether nanocrystal particle sizes of 160 nm. The saturation solubility of the artemether nanocrystals was 
substantially increased to 900 µg/mL, compared to the raw artemether solubility in water (145 µg/mL) and 
artemether microparticles in stabilizer solution (300 µg/mL). Results of in vitro studies showed significant 
antimalarial effect of artemether against Plasmodium falciparum and Plasmodium vivax cultures. The IC50 
(median lethal oral dose) values of artemether nanocrystals were 28-54-fold lower than the IC50 values of 
unprocessed drug and 13-21-fold lower than the IC50 values of marketed artemether tablets, respectively. A 
2 mg/kg dosing of artemether nanocrystals showed significantly higher (89%) reduction in parasitemia 
against Plasmodium vivax compared with unprocessed artemether (27%) or the marketed artemether tablets 
(45%) (Shah et al., 2016). An acute toxicity study in Swiss albino mice demonstrated that the LD50 value of 
artemether nanocrystals was between 1,500 mg/kg and 2,000 mg/kg when given orally.  
Professor Rainer H. Müller and his research group has extensively studied also the oral drug delivery route, 
see for example Müller et al. (2001; 2006). The group has developed and optimized oral nanoformulations 
for cyclosporine A (2%) as solid lipid nanoparticles (SLN™, mean size 157 nm) and as nanocrystals (mean size 
962 nm). The encapsulation of cyclosporine A in SLN was 96%, while the nanocrystals were composed of 
100% of the drug. The blood profiles in young pigs after the oral administration revealed that for the drug 
nanocrystals most of the blood concentration values were low with high differences between the measuring 
time points and the tested animals. On the contrary, administration of cyclosporine-loaded SLN led to higher 
mean plasma profiles with low variations, while at the same time successfully avoided the potential side 
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effects by high blood concentrations, as was the case with the commercial microemulsion product of 
cyclosporine-A (Sandimmun®). 
Overall, pharmaceutically relevant nanocrystal formulations have been widely studied and commercialized 
with improved solubility/dissolution properties of poorly soluble drug materials. Nanocrystals are often 
formed from 100% drugs covered by stabilizer layer(s) in relatively simple and efficient manufacturing 
processes.  
Conclusions 
Nanosizing is simple and straightforward way to improve solubility properties of poorly soluble drug 
materials, and often even very small changes in particle size are enough for acceptable product 
performance.  The most important property of drug nanocrystals is increased dissolution rate due to the 
smaller particle size, but in nanoscale physical properties like solubility are also different from 
thermodynamic solubility value. These two important properties of drug nanocrystals can be utilized in 
order to reach higher bioavailability with nanocrystal formulations, and drug nanocrystals are one versatile 
option for improving solubility properties of BCS class II and in some cases also class IV drugs. There are 
already a lot of studies and marketed products with different formulations in various administration routes 
based on drug nanocrystals. In the future the research will be headed more on functional properties of the 
stabilizers utilized in drug nanocrystals, role of supersaturation and QbD approach in formulation design, 
and drug targeting applications for example in cancer therapeutics or theranostics through the attachment 
of protecting layers and targeting ligands on the surfaces of the nanosystems.  
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Figure Captions: 
Figure 1. Apparent concentration-distance profiles from UV imaging of indomethacin nanocrystals (particle 
size 580 nm) and micron sized particles with two different stabilizers (poloxamers F68 and F127) as well as 
bulk indomethacin at 5, 15 and 30 min time points: (A) F68 stabilized nanocrystals, (B) F68 stabilized micron 
sized particles, (C) F127 stabilized nanocrystals, (D) F127 stabilized micron sized particles and (E) bulk 
indomethacin. (Reprinted from Sarnes et al., 2013 with permission from Elsevier). 
Figure 2. Plasma concentration profiles of itraconazole and OH-itraconazole in rats after oral administration 
of Sporanox® granules, three nanocrystalline formulations (HFBI, HFBI + NFC, HFBI-DCBD + NFC) and 
itraconazole microsuspension. (Reprinted from Valo et al., 2011, with permission from Elsevier.) 
Figure 3. Impact of PVP on maintaining the supersaturated state of amorphous indomethacin for 
indomethacin-PVP solid dispersion (Figures a,c,e) and for amorphous indomethacin dissolved in aqueous 
PVP solution (Figures b, d, f) in pH 5.5 at 25 °C. Figures a and b: PCA scores plots of the IR spectra of 
indomethacin samples (arrows indicating the path of crystallization); Figures c and d: IR spectras of 
indomethacin samples; and Figure e and f: concentration-time profiles showing the maintenance of 
supersaturated state in the presence of PVP. (Reprinted from Surwase et al., 2015 with permission from 
Elsevier.) 
Figure 4. TEM figures of F127 stabilized paclitaxel nanocrystals. Drug surfactant ratio (A) drug:surfactant 
ratio 1:10 (w/w) and (B) 1:20 (w/w). Scale bar is 200 nm. (Reprinted from Deng et al., 2010 with permission 
from Elsevier). 
Figure 5. In vivo antitumor efficacy of paclitaxel formulations in mice: curves from top to down: Control, 
PTX paclitaxel nanosuspension, PTX-Trf paclitaxel transferrin nanosuspension and Taxol®. (Reprinted from 
Lu et al., 2014 with permission from Elsevier). 
Figure 6. Bioavailability in rats of itraconazole and OH-itraconazole after per oral administration of 
nanocrystalline itraconazole formulations: nanosuspension (ITC-NPs), freeze dried nanosuspension (freeze 
dried ITC-NPs), granulated nanosuspension (granulated ITC-NPs), Sporanox® granules and physical mixture 
(mean ± sem, n = 5–6). (Reprinted from Sarnes et al., 2014 with permission from Elsevier). 
